ライフサイエンスコーパス: prothrombin time

1 ed by the international normalized ratio for prothrombin time).

2 rked thrombocytopenia or prolongation in the prothrombin time.

3 eserves normal liver function as assessed by prothrombin time.

4 candidacy for liver transplant and prolonged prothrombin time.

5 or Xa inhibitor which has a strong impact on prothrombin time.

6 ha fetal protein cholesterol, triglycerides, prothrombin time.

7 nogen at the time of surgery, with unchanged prothrombin time.

8 brain "thromboplastic" activity used in the prothrombin time.

9 m: age, Glasgow Coma Scale, base excess, and prothrombin time.

10 d the international normalized ratio for the prothrombin time.

11 g activated partial thromboplastin times and prothrombin times.

12 irect bilirubin (0.13 versus 0.1, P = 0.01), prothrombin time (14.4 versus 12.4, P = 0.002), and AST-

13 ssue factor; 60 nM lactadherin prolonged the prothrombin time 150% versus 20% for 60 nM annexin V.

14 ificantly decreased in the small group, with prothrombin time 18.2 +/- 2.2 seconds versus 14.8 +/- 1.

15 had ascites (91%), jaundice (88%), elevated prothrombin time (18 +/- 3 seconds), and hypoalbuminemia

16 nd 2.3 [0.8-8.7] microg/mL, p = .05), longer prothrombin time (19.3 [15.4-25.9] vs. 15.3 [14.8-17.1],

17 d heparin followed by warfarin for 3 months (prothrombin time, 20 to 25 seconds).

18 >5 weeks after onset; P < .01), more severe prothrombin time abnormalities (26% vs. 0% with >3 secon

19 C was confirmed within 4 hours by changes in prothrombin time, activated partial thromboplastin time,

20 Measurements included prothrombin time, activated partial thromboplastin time,

21 unction was assessed by thrombin generation, prothrombin time, activated partial thromboplastin time,

22 thological grades, total bilirubin, albumin, prothrombin time, alpha-fetoprotein, and tumor number, w

23 S) status, ABO blood group, bilirubin level, prothrombin time, ammonia level, creatinine level, and r

24 old and fourfold prolonged clotting times in prothrombin time and activated partial prothrombin time

25 The mutant was inactive in both prothrombin time and activated partial thromboplastin ti

26 ere present in the patient's plasma and both prothrombin time and activated partial thromboplastin ti

27 ory studies demonstrated prolongation of the prothrombin time and activated partial thromboplastin ti

28 s prothrombinase activity and increases both prothrombin time and activated partial thromboplastin ti

29 Laboratory findings (such as prothrombin time and bilirubin level), complications, an

30 There is no doubt that prothrombin time and congeners tests are unable to predi

31 and absolute lymphocyte counts and increased prothrombin time and creatinine and amylase levels.

32 indicative of acute kidney injury; prolonged prothrombin time and decreased fibrinogen, indicative of

33 Knockout FVII mice demonstrated a delayed prothrombin time and decreased plasma FVII expression.

34 Prothrombin time and INR were measured before and after

35 varices demonstrated a significantly longer prothrombin time and lower platelet count, there was no

36 d patients had more severe injury, prolonged prothrombin time and partial thromboplastin time (PTT),

37 y 3% of normal clotting activity in modified prothrombin time and partial thromboplastin time assays,

38 ase, and cholesterol levels were normal, but prothrombin time and partial thromboplastin time were pr

39 ransplanted baboons (high D-dimer, prolonged prothrombin time and partial thromboplastin time, and fa

40 area, preoperative hematocrit, preoperative prothrombin time and prior myocardial infarction.

41 er 90%, whereas fVII knockdown prolonged the prothrombin time and reduced fVII activity to a similar

42 alth Evaluation II score, modified MODS, and prothrombin time and the lowest platelet counts, whereas

43 re statistically similar with regard to age, prothrombin time and total bilirubin.

44 olongation of the partial thromboplastin and prothrombin times and hyperfibrinolysis with low levels

45 Lupus anticoagulants can influence prothrombin times and lead to INRs that do not accuratel

46 try (glucose, lactate, liver function tests, prothrombin time) and to assess liver regenerative respo

47 ther thrombocytopenia or prolongation of the prothrombin time, and (3) the resources used for large-v

48 fferences including plasma fibrinogen level, prothrombin time, and activated partial thromboplastin t

49 levels, admission lactate levels, platelets, prothrombin time, and activated partial thromboplastin t

50 rotein extracts were used for Western blots, prothrombin time, and activated partial thromboplastin t

51 ine aminotransferase, lactate dehydrogenase, prothrombin time, and alkaline phosphatase, with grafts

52 arkers of graft function (lactate, glycemia, prothrombin time, and bile production), inflammation (tu

53 orts, activated partial thromboplastin time, prothrombin time, and deep vein thrombosis.

54 or age, gender, total bilirubin, creatinine, prothrombin time, and diagnosis.

55 ls, International Normalized Ratio (INR) for prothrombin time, and etiology of liver disease.

56 se patient participation, self-monitoring of prothrombin time, and guideline-based management of warf

57 Mean activated partial thromboplastin time, prothrombin time, and international normalized ratio wer

58 tics and routine coagulation tests including prothrombin time, and international normalized ratio, ac

59 Serum albumin, prothrombin time, and platelet count at presentation wer

60 , D-dimer, alpha-2-antiplasmin, antitrombin, prothrombin time, and platelet count) and the DIC score

61 , sex, underlying liver disease, hemoglobin, prothrombin time, and platelet count.

62 d include serum acetaminophen concentration, prothrombin time, and serum bilirubin and transaminase c

63 story model, namely age, bilirubin, albumin, prothrombin time, and the presence or absence of edema.

64 th a relatively modest 1.25-fold increase in prothrombin times, and in the absence of hemorrhagic com

65 irubin, albumin, creatinine, and hemoglobin; prothrombin time; and numbers of platelets and white cel

66 ne aminotransferase (AST/ALT), and prolonged prothrombin time are the earliest indicators of cirrhosi

67 he activated partial thromboplastin time and prothrombin time, as well as activated partial thrombopl

68 h as endotoxin-induced whole blood clotting, prothrombin time, as well as factor X and factor IX acti

69 ffective inhibitor of a modified whole blood prothrombin time assay in which clotting was initiated b

70 es in prothrombin time and activated partial prothrombin time assays, respectively (P < .001).

71 ivated protein C (APC):protein S in modified prothrombin time assays, the effects of depleting endoge

72 During warfarin management, variability in prothrombin time-based international normalized ratio (P

73 inverse correlation with platelet count and prothrombin time but not with serum albumin level.

74 r months to years, to maintain a near-normal prothrombin time can reverse the coagulopathy associated

75 ed activated partial thromboplastin time and prothrombin time clotting times to baseline at 60 mins.

76 protein S anticoagulant activity in modified prothrombin-time clotting assays.

77 asminogen activator inhibitor-1 activity and prothrombin time compared to children with MOF without t

78 control of ascites, level of encephalopathy, prothrombin time, concentration of serum albumin, and co

79 e, grade of encephalopathy, serum bilirubin, prothrombin time, creatinine, serum phosphorus, phosphor

80 EVTF activity, fibrinogen, activated partial prothrombin time, D-dimer, tissue plasminogen activator

81 cipient mechanical ventilation, preoperative prothrombin time, donor sodium level, donor length of ho

82 f seven serine proteases, and FVII-deficient prothrombin time EC2x = 1.2 muM.

83 sly unrecognized findings included prolonged prothrombin times, elevated platelet counts and serum ph

84 A combination of prothrombin time, endothelium-derived CD105-microparticl

85 eding, low systolic blood pressure, elevated prothrombin time, erratic mental status, and unstable co

86 markers for liver function are bilirubin and prothrombin time expressed as International Normalized R

87 survival was independently predicted by PS, prothrombin time, extrahepatic tumor spread, macrovascul

88 Acetazolamide improved prothrombin time, factor X, and antithrombin.

89 othrombin were altered by this treatment but prothrombin times, factor VII activity, prothrombin F-1

90 The new factor II and X (Fiix)-prothrombin time (Fiix-PT) and Fiix-normalized ratio (Fi

91 thod affected only by factors II and X (Fiix-prothrombin time [Fiix-PT]) compared with standard PT-IN

92 s thrombin potential and partial reversal of prothrombin time following 50 IU/kg.

93 r = 2 mg/dL, Glasgow Coma Score less than 6, prothrombin time greater than 15 seconds, blood urea nit

94 el greater than or equal to 250 mumol/L, and prothrombin time greater than or equal to 30 seconds was

95 rum albumin level, 2.58 g/dL), coagulopathy (prothrombin time > 20 s compared with that of a normal c

96 tory insufficiency, age > or = 65 years, and prothrombin time > or = 16 seconds.

97 patients (26%) presented with coagulopathy (prothrombin time > or = 3 seconds prolonged).

98 an absolute platelet count <100 x 10/L; b) a prothrombin time >15.0 secs; c) a 20% decrease in platel

99 erval [CI], 5.59-40.22; P < 0.0001), minimum prothrombin time >50 % (OR, 4.50; 95% CI, 1.67-13.46; P

100 he use of sensitive reagents (especially for prothrombin time) has resulted in increased incidence of

101 ody mass index (HR 1.40; 95% CI: 1.01-1.95), prothrombin time (HR 0.79; 95% CI: 0.70-0.90), serum alb

102 hallmark diagnostic features are a prolonged prothrombin time (ie, an international normalized ratio

103 Prothrombin time improved to normal in all patients 1 ye

104 actors, and treatment of prolongation of the prothrombin time in critically ill patients using the in

105 in platelets; and d) a >0.3-sec increase in prothrombin time in predicting outcome in patients with

106 ma activated partial thromboplastin time and prothrombin time increased over 10-fold during the bleed

107 eatinine, international normalized ratio for prothrombin time (INR), and the cause of the underlying

108 had hepatic encephalopathy; median levels of prothrombin time, INR, and total bilirubin were, respect

109 fact that screening coagulation tests (APTT, prothrombin time--INR) are often used as though they are

110 Prothrombin time international normalized ratio (INR) wa

111 owed that patient age older than 65 years, a prothrombin time international normalized ratio greater

112 rinogen, activated partial prothrombin time, prothrombin time international normalized ratio, D-dimer

113 lyzed for coagulation profiling (fibrinogen, prothrombin time, international normalized ratio, activa

114 uality improvement study assesses changes in prothrombin time, international normalized ratio, and pa

115 rats had significantly lower blood ammonia, prothrombin time, international normalized ratio, and TG

116 24.77 vs 73.17 + 53.71 IU/L; P = 0.04), and prothrombin time-international normalized ratio (1.16 +

117 Postoperative serum bilirubin and prothrombin time-international normalized ratio (PT-INR)

118 sferase; POD3 aspartate aminotransferase and prothrombin time-international normalized ratio; postope

119 ctivity levels can serve as a substitute for prothrombin time/international normalized ratio (PT/INR)

120 , specifically baseline levels of bilirubin, prothrombin time/international normalized ratio, and Mod

121 Use of the INR to standardize prothrombin times is invalid for some patients with lupu

122 clotting test with the quick clotting time (prothrombin time), it was possible to diagnose factor VI

123 inemia, decreased serum fibrinogen, elevated prothrombin time), lactic acidosis, and hepatic steatosi

124 e influence of several anticoagulants on the prothrombin time limits its diagnostic value.

125 teristics, the most important being a higher prothrombin time, lower bilirubin, and lower incidence o

126 fined according to the "50-50 criteria" (ie, prothrombin time <50% and serum bilirubin >50 micromol/L

127 /= 127 g/L; odds ratio, 0.99; p < 0.01), and prothrombin time (</= 58%; odds ratio, 0.98; p < 0.05) w

128 We analyzed altered prothrombin time (measured as international normalized r

129 tment of warfarin treatment using a portable prothrombin time monitor may be effective and safe.

130 The results of prothrombin time monitoring should be reported as the In

131 factors that influence dosing, conscientious prothrombin time monitoring, and sage dosage adjustment

132 ially bleeding), inconveniences (the cost of prothrombin time monitoring, the need for rigid dietary

133 notransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 76%, 81%, 50%, and 83% of

134 rtate aminotransferase, cholinesterases, and prothrombin time not differed in 2 groups.

135 me (ie, an international normalized ratio of prothrombin time of >=1.5) and any degree of mental stat

136 hromboplastin time of 49.2 seconds, a normal prothrombin time of 12.4 seconds, and a platelet count o

137 mg/dL, alanine aminotransferase of 106 IU/L, prothrombin time of 14.2 sec, and serum albumin of 2.9 g

138 lation panel was unremarkable and included a prothrombin time of 15.4 seconds, an international norma

139 s of liver disease (P = 0.01) and a pre-TIPS prothrombin time of 17 seconds or more (P = 0.016).

140 -183X also had a maximal prolongation of the prothrombin time of 7.6- versus 1.9-fold for A-183, maki

141 national normalized ratio of more than 11, a prothrombin time of more than 120 seconds, and an activa

142 Mean prothrombin time on postoperative day 2 was 14.9 +/- 1.6

143 times are best suited for dabigatran and the prothrombin time or the anti-FXa for rivaroxaban.

144 states that routine correction of prolonged prothrombin time or thrombocytopenia is not required is

145 The practice of testing patients with the prothrombin time or viscoelastometry and using arbitrary

146 ndex (p < .02), Lung Injury Score (p < .02), prothrombin time (p < .02), and activated partial thromb

147 0.0001), alkaline phosphatase (P = 0.0009), prothrombin time (P = 0.0005), and maximal vital capacit

148 h baseline esophageal varices (P = 0.01) and prothrombin time (P = 0.002), but not with disease progr

149 wer serum albumin levels (P=0.04) and higher prothrombin times (P<0.001) at presentation.

150 Prolonged prothrombin time, partial activated thromboplastin time,

151 agulation changes were assessed by prolonged prothrombin time, partial activated thromboplastin time,

152 on of cFVIIa resulted in a shortening of the prothrombin time, partial correction of the whole blood

153 ate aminotransferase) and coagulation times (prothrombin time, partial thromboplastin time) indicated

154 were no differences in thrombin generation, prothrombin time, partial thromboplastin time, activated

155 of fibrinogen and platelets and increases of prothrombin time, partial thromboplastin time, and fibri

156 gradation products, whereas abnormalities in prothrombin time, partial thromboplastin time, and plate

157 ly obtained measurements of laboratory-based prothrombin time, partial thromboplastin time, complete

158 Platelet counts, with plasma prothrombin time, partial thromboplastin time, fibrinoge

159 iabetes mellitus, relative lymphocyte count, prothrombin time, peripheral artery disease, and contral

160 emia, renal insufficiency, hyponatremia, and prothrombin time prolongation (all P < 0.001).

161 Prothrombin time prolongation is prevalent in critically

162 EVTF activity, fibrinogen, activated partial prothrombin time, prothrombin time international normali

163 l for analysis of partial thromboplastin and prothrombin times, prothrombin fragments 1+2, fibrinogen

164 ce antigen positive, grade 1 encephalopathy, prothrombin time (pt) >100 sec, F7<1%, NH3 150 micromol/

165 Coagulation studies revealed prothrombin time (PT) 13.5 seconds, internationalized no

166 The low hemolysis of 2.39% with short prothrombin time (PT) and activated partial thromboplast

167 ale was referred for evaluation of prolonged prothrombin time (PT) and activated partial thromboplast

168 Increases in prothrombin time (PT) and international normalised ratio

169 Frequent prothrombin time (PT) and international normalized ratio

170 Prothrombin time (PT) and the associated international n

171 Primary end points were changes in the prothrombin time (PT) and the partial thromboplastin tim

172 vated partial thromboplastin time (aPTT) and prothrombin time (PT) are clinical tests commonly used t

173 Cirrhotic patients with a prolonged prothrombin time (PT) are known to have low levels of fa

174 vated partial thromboplastin time (APTT) and prothrombin time (PT) are less sensitive and may be norm

175 rs of TF-dependent clotting as measured in a prothrombin time (PT) clotting assay and had no effect o

176 hTFAA prolongs prothrombin time (PT) determined with human plasma and r

177 /dL, platelet count less than 100000/microL, prothrombin time (PT) greater than or equal to 16 second

178 neral overview of the plasmatic coagulation, prothrombin time (PT) tests are frequently combined with

179 se [AST] and alanine transaminase [ALT]) and prothrombin time (PT) values achieved by each patient du

180 itial levels of albumin, platelet count, and prothrombin time (PT) were predictive risk factors for d

181 ts were performed to extract RCIs, including prothrombin time (PT), activated partial thromboplastin

182 Standard coagulation assays, including prothrombin time (PT), activated partial thromboplastin

183 patient, whole blood lactate concentration, prothrombin time (PT), and alanine aminotransferase (ALT

184 nged the partial thromboplastin time (APTT), prothrombin time (PT), and bleeding time (BT).

185 ctivated partial thromboplastin time (APTT), prothrombin time (PT), international normalized ratio (I

186 Prothrombin time (PT), partial thromboplastin time (PTT)

187 their plasma coagulation indices, including prothrombin time (PT), partial thromboplastin time (PTT)

188 This included prothrombin time (PT), prothrombin activity, lactate deh

189 , in addition to donor age, total bilirubin, prothrombin time (PT), retransplantation, and warm and c

190 Prothrombin time (PT), total bilirubin, serum ammonia, a

191 ed lactate dehydrogenase (LDH), and elevated prothrombin time (PT).

192 ortable testing of blood coagulation time or prothrombin time (PT).

193 e (MA), LY30] with their corresponding CCTs [prothrombin time (PT)/activated partial thromboplastin t

194 er, there was no difference in elevations of prothrombin times (PT) or improvement in the vasoconstri

195 Platelet counts, prothrombin times (PT), and levels of fibrinogen, D-dime

196 ongly with anti-factor Xa activity (r=0.97), prothrombin time (r=0.77), and international normalized

197 were recruited within 72 hours of their peak prothrombin time (range 42-120 seconds).

198 nsfusion (detection rate of 71%, vs. 43% for prothrombin time ratio >1.2, p < .001).

199 traumatic coagulopathy defined as laboratory prothrombin time ratio >1.2.

200 Point-of-care prothrombin time ratio had reduced agreement with labora

201 ratio had reduced agreement with laboratory prothrombin time ratio in patients with acute traumatic

202 In trauma hemorrhage, prothrombin time ratio is not rapidly available from the

203 coagulation therapy and the deviation in the prothrombin time ratio using Cox and Poisson regression,

204 Prothrombin time ratio was calculated and acute traumati

205 coagulation therapy and the deviation in the prothrombin time ratio were much stronger predictors of

206 to the mean warfarin dose and dose-adjusted prothrombin time ratio.

207 rtial thromboplastin time (aPTT) reagent and prothrombin time reagent and reduces the anticoagulant e

208 As anticipated, prothrombin time remained unchanged compared with baseli

209 Laboratory prothrombin time results were available at a median of 7

210 c transaminase (U/L), bilirubin (mg/dL), and prothrombin time (sec) during the first postoperative we

211 rats resulted in significant improvement in prothrombin time, serum albumin and bilirubin levels, he

212 inotropic score, aspartate aminotransferase, prothrombin time, serum creatinine, need for renal repla

213 otransferase and total bilirubin, platelets, prothrombin time, sex, and age were associated with BNR

214 flected by changes in the platelet count and prothrombin time that convey prognostic information.

215 ximum amplitude to 75% +/- 3%; and prolonged prothrombin time to 113% +/- 2%, partial thromboplastin

216 available (international normalized ratio of prothrombin time, total bilirubin, and creatinine).

217 ith CO maintained liver function with normal prothrombin times versus a 2-fold prolongation in contro

218 dure mean international normalized ratio for prothrombin time was 1.7 +/- 0.46 (range, 0.9-8.7; inter

219 Postoperative day 2 prothrombin time was 13+/-1 sec.

220 Baseline prothrombin time was 28+/-0.8 secs (n=8) and followed a

221 the international normalized ratio (INR) of prothrombin time was available, MELD correlated with out

222 Mean prothrombin time was shorter in arterial strokes (P < .0

223 olongation of the partial thromboplastin and prothrombin times was only observed with an increased BD

224 otransferase, aspartate aminotransferase,and prothrombin time were not significantly different over t

225 Effects on prothrombin time were partially reversed at 50 IU/kg.

226 Activated partial thromboplastin time and prothrombin time were shortened by these proteinases, wi

227 acetaminophen self-poisoning and a prolonged prothrombin time were studied.

228 Prothrombin times were determined by using several throm

229 um aminotransferase and bilirubin levels and prothrombin times were higher in recipients of older tha

230 nfected mice compared with controls, whereas prothrombin times were normal, suggesting an isolated ab

231 All prothrombin times were normalized within 4 days of trans

232 icoagulants who were not receiving warfarin, prothrombin times were often elevated and varied signifi

233 lupus anticoagulants often have a prolonged prothrombin time, which may complicate management of ant